RayKnowChina Research Map
Shortlist

Not yet recruitingPancreatic cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06913218, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histopathology or cytology confirmed resected PDAC with macroscopic complete resection (R0 and R1)

    Inclusion criterion 3

  3. Pancreatic cancer surgical staging per AJCC 8th edition staging: T 1-3, N0-2, M0

    Inclusion criterion 4

  4. ECOG 0 or 1

    Inclusion criterion 5

  5. Active malignancy within the last 3 years

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06913218, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily signed the informed consent form and complied with protocols requirements
  • Patients with radiographically resectable primary pancreatic tumors
  • Histopathology or cytology confirmed resected PDAC with macroscopic complete resection (R0 and R1)
  • Pancreatic cancer surgical staging per AJCC 8th edition staging: T 1-3, N0-2, M0
  • ECOG 0 or 1
  • Life expectancy ≥ 6 months
  • Surgical complications have recovered,
  • Adequate organ function
  • Patients with fertility are willing to use an adequate method of contraception.

Exclusion Criteria:

  • The presence of other pathologic types
  • Participating in another clinical study
  • Have received treatment for pancreatic cancer, including chemotherapy, radiation therapy, targeted therapy, immunotherapy,etc
  • Plan to receive a live-attenuated vaccine within 28 days prior to initiation of study treatment or during the study treatment or within 90 days after the end of study treatment
  • Severe infection occurs within 4 weeks prior to the first dose
  • Requiring systemic therapy with glucocorticoids or other immunosuppressive drugs within 14 days prior to initial administration.
  • Acute pancreatitis or subclinical pancreatitis
  • Active autoimmune disease
  • Allergic to immunotherapies and related drugs
  • History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • Splenectomy history
  • Active tuberculosis
  • Known or highly suspected history of interstitial pneumonia.
  • Clinically significant liver disease
  • Uncontrolled or severe cardiovascular disease.
  • Severe bleeding tendency or history of coagulopathy
  • Active malignancy within the last 3 years
  • Active syphilis infection
  • Any other situations that are not suitable for inclusion in this study judged by investigator.

Quoted from ClinicalTrials.gov, NCT06913218, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06913218, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06913218